San Francisco, California, Sept 01, 2017: A recently added report by TMR Research, titled, “Inherited Metabolic Disorders Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025,” sheds light on important aspects of the market such as its size, competitive dynamics, and growth prospects.
Treatment of inherited metabolic disorders (IMD), genetic conditions resulting in metabolism issues, entails dietary supplementation, dietary restrictions, drugs that thwart or regulate metabolism, gene therapy, transplantation of the concerned organ, and dialysis in extreme cases. At present, the dietary supplements is the most popular form of treatment. However, with constant thrust on research and development, more condition-specific therapeutics are likely to emerge in the upcoming years.
Most of such metabolic disorders can be tamed with certain changes in the diet and lifestyle of the person. Some inherited metabolic disorders (IMDs) are, however, life threatening.
The market for inherited metabolic disorders (IMD) lies mostly with the Caucasian and African American populations of world, especially in North America, Europe, Australia, and Africa, followed by the minority populations from South Asia and East A.
As per a release by Public Health Genetics U.K., IMD afflicts nearly one in every 2,500 to 5,000 individuals and nearly 300 to 600 new cases are found in the U.K. The specificity and high risk affinity of IMD differs from case to case. Some disorders like familial cylomicronemia occur mostly in Caucasians and others occur primarily in African Americans.
The overall estimated global populations of IMD individuals lie in few millions. The niche category of this segment gives little market for specific condition-related products. However, the implications of therapy are huge as some treatments have the potential to completely eradicate these disorders.
A noticeable trend in the global inherited metabolic disorders market is the rising popularity of oral insulin therapies. Up until a while back, insulin injections were mainly administered via subcutaneous tissues which also gave rise to the risk of infection and hypersensitivity reactions, emboli, and local pain.
High cost was another issue. This paved the way for oral insulin which does away with pricks and shots and other complications resulting from existing therapies. Oral administration of insulin results in increased patient comfort and compliance, reduced risk of infection, simpler application, and low costs.
Currently, the global metabolic disorders therapeutics market is consolidated in nature with a few players dominating. They are focused on research and development to come up with better therapeutic products. Some such leading players profiled in the report are Novo Nordisk, Merck, Eli Lily, AstraZeneca, and Sanofi.
Click on the link below to request a sample copy of the report